Lalitpur: In a strategic move to catalyze growth in the pharmaceutical sector, the Uttar Pradesh government is set to invest approximately Rs 8,000 crore in a groundbreaking bulk drug park in Lalitpur. The proposed mega enclave, sprawling across 1,472 acres in the arid Bundelkhand region, is poised to establish Uttar Pradesh as a prominent center for pharmaceuticals, generic medicines, and medical devices in South Asia. This ambitious initiative aligns with the state’s vision to contribute significantly to the projected $130 billion domestic pharmaceutical industry by 2030.
The Lalitpur bulk drug park, spearheaded by the UP State Industrial Development Authority (UPSIDA), entails the immediate development of 300 acres of land. The Uttar Pradesh government has already inked 236 Memorandum of Understanding (MoU) agreements, amounting to Rs 11,000 crore, with various companies and consortiums committed to establishing their manufacturing plants within the park.
Dedicated to bulk drugs, starting/raw materials, and active pharmaceuticals, the project operates under the newly formulated UP Pharma Policy 2023. As part of the strategic infrastructure, the state has collaborated with Adani Gas for the supply of piped natural gas (PNG) to the park, ensuring seamless operations.
The significance of this venture extends beyond infrastructural development. Uttar Pradesh has joined forces with esteemed scientific institutions, including the Council of Scientific and Industrial Research (CSIR) and the Defence Research and Development Organisation (DRDO), serving as knowledge partners for the park. These collaborations aim to advance research and development (R&D) efforts focused on innovative drugs and medical devices, addressing severe and chronic diseases not only in India but also in 200 other countries.
With a goal to escalate its share in India’s pharmaceutical industry from 2 percent to 10-12 percent, Uttar Pradesh aims to capitalize on its strategic location and conducive business environment. While India currently leads the global generic medicines market by volume, commanding a 20 percent market share, it imports 80 percent of its domestic medical devices needs.
The Lalitpur bulk drug park emerges as a transformative initiative, poised to bridge these gaps and position Uttar Pradesh as a key player in the ever-evolving landscape of the pharmaceutical and medical devices sector.
